P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-04-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000829624.40467.0d |
| _version_ | 1827333337001230336 |
|---|---|
| author | R Popat A Badros S Kumar P Rodriguez-Otero A Cohen S Manier P Voorhees F Gay R Rifkin T Martin A Chari K Weisel A Farooq B Jeng W Chng H Lee J Berdeja V Jadhav A Tosolini L Eliason A Palumbo M Dimopoulos S Lonial S Trudel P Richardson E Terpos |
| author_facet | R Popat A Badros S Kumar P Rodriguez-Otero A Cohen S Manier P Voorhees F Gay R Rifkin T Martin A Chari K Weisel A Farooq B Jeng W Chng H Lee J Berdeja V Jadhav A Tosolini L Eliason A Palumbo M Dimopoulos S Lonial S Trudel P Richardson E Terpos |
| author_sort | R Popat |
| collection | DOAJ |
| first_indexed | 2024-03-07T17:20:50Z |
| format | Article |
| id | doaj.art-1a447792f2ae466386e6f2c5a706d549 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T17:20:50Z |
| publishDate | 2022-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-1a447792f2ae466386e6f2c5a706d5492024-03-02T19:48:45ZengWileyHemaSphere2572-92412022-04-016181810.1097/01.HS9.0000829624.40467.0d202204002-00036P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?R Popat0A Badros1S Kumar2P Rodriguez-Otero3A Cohen4S Manier5P Voorhees6F Gay7R Rifkin8T Martin9A Chari10K Weisel11A Farooq12B Jeng13W Chng14H Lee15J Berdeja16V Jadhav17A Tosolini18L Eliason19A Palumbo20M Dimopoulos21S Lonial22S Trudel23P Richardson24E Terpos251 University College London Hospitals, NHS Foundation Trust, London (UK)2 University of Maryland School of Medicine, Baltimore (USA)3 Mayo Clinic, Rochester (USA)4 Clinica Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra, Navarra (Spain)5 Perelman School of Medicine, University of Pennsylvania, Philadelphia (USA)6 Lille University Hospital, Lille (France)7 Levine Cancer Institute - Atrium Health, Charlotte (USA)8 University of Turin, Turin (Italy)9 UC Health, Steamboat Springs (USA)10 University of California San Francisco, San Francisco (USA)11 Mount Sinai, New York (USA)12 University Medical Center of Hamburg-Eppendorf, Hamburg (Germany)13 University of Chicago Medical Center, Chicago (USA)2 University of Maryland School of Medicine, Baltimore (USA)14 National University Cancer Institute of Singapore, Singapore15 The University of Texas MD Anderson Cancer Center, Houston (USA)16 Sarah Cannon Research Institute, Nashville (USA)17 GlaxoSmithKline, Bengaluru (India), 17*Upper Providence (USA), 17†Zug (Switzerland)17 GlaxoSmithKline, Bengaluru (India), 17*Upper Providence (USA), 17†Zug (Switzerland)17 GlaxoSmithKline, Bengaluru (India), 17*Upper Providence (USA), 17†Zug (Switzerland)17 GlaxoSmithKline, Bengaluru (India), 17*Upper Providence (USA), 17†Zug (Switzerland)18 National and Kapodistrian University of Athens School of Medicine, Athens (Greece)19 Winship Cancer Institute of Emory University, Atlanta (USA)20 Princess Margaret Cancer Centre, Toronto (Canada)21 Dana-Farber Cancer Institute, Boston (USA)18 National and Kapodistrian University of Athens School of Medicine, Athens (Greece)http://journals.lww.com/10.1097/01.HS9.0000829624.40467.0d |
| spellingShingle | R Popat A Badros S Kumar P Rodriguez-Otero A Cohen S Manier P Voorhees F Gay R Rifkin T Martin A Chari K Weisel A Farooq B Jeng W Chng H Lee J Berdeja V Jadhav A Tosolini L Eliason A Palumbo M Dimopoulos S Lonial S Trudel P Richardson E Terpos P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN? HemaSphere |
| title | P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN? |
| title_full | P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN? |
| title_fullStr | P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN? |
| title_full_unstemmed | P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN? |
| title_short | P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN? |
| title_sort | p13 can patient reported ocular symptoms guide dose modifications in patients with relapsed refractory multiple myeloma receiving belantamab mafodotin |
| url | http://journals.lww.com/10.1097/01.HS9.0000829624.40467.0d |
| work_keys_str_mv | AT rpopat p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin AT abadros p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin AT skumar p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin AT prodriguezotero p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin AT acohen p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin AT smanier p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin AT pvoorhees p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin AT fgay p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin AT rrifkin p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin AT tmartin p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin AT achari p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin AT kweisel p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin AT afarooq p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin AT bjeng p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin AT wchng p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin AT hlee p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin AT jberdeja p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin AT vjadhav p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin AT atosolini p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin AT leliason p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin AT apalumbo p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin AT mdimopoulos p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin AT slonial p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin AT strudel p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin AT prichardson p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin AT eterpos p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin |